decitabine

[Blood] Scientists analyzed the effect of decitabine on T-cell subpopulations in immune thrombocytopenia in vitro and in vivo. They found that low-dose decitabine promoted the generation and differentiation of regulatory T cells and augmented their immunosuppressive function.

[Bio-Path Holdings, Inc.] Bio-Path Holdings, Inc. announced that the US FDA has reviewed and cleared the Investigational New Drug application for BP1002, the company’s second drug candidate, for an initial Phase I/Ib clinical trial that will evaluate the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.

[Haematologica] The authors reported the discovery of a novel class of orally bioavailable DNA methyltransferase (DNMT1)-selective inhibitors as exemplified by GSK3482364.

[Leukemia] Investigators discuss recent therapeutic advances and innovative treatment strategies in chronic myelomonocytic leukemia (CMML), including global and molecularly targeted approaches, and discuss what may help to make progress in the design of rationally derived and disease-modifying therapies for CMML.

[AbbVie, Inc.] AbbVie, Inc. announced that the European Commission has approved VENCLYXTO® in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

[Leukemia] The authors provide insights into the mode of action of HMA, mechanisms of resistance to this treatment, and strategies to overcome HMA resistance including next-generation HMA and HMA-based combination therapies.